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BACKGROUND
Bleeding in early pregnancy is strongly associated with pregnancy loss. Progester-
one is essential for the maintenance of pregnancy. Several small trials have sug-
gested that progesterone therapy may improve pregnancy outcomes in women who 
have bleeding in early pregnancy.
METHODS
We conducted a multicenter, randomized, double-blind, placebo-controlled trial to 
evaluate progesterone, as compared with placebo, in women with vaginal bleeding 
in early pregnancy. Women were randomly assigned to receive vaginal supposito-
ries containing either 400 mg of progesterone or matching placebo twice daily, 
from the time at which they presented with bleeding through 16 weeks of gesta-
tion. The primary outcome was the birth of a live-born baby after at least 34 weeks 
of gestation. The primary analysis was performed in all participants for whom 
data on the primary outcome were available. A sensitivity analysis of the primary 
outcome that included all the participants was performed with the use of multiple 
imputation to account for missing data.
RESULTS
A total of 4153 women, recruited at 48 hospitals in the United Kingdom, were 
randomly assigned to receive progesterone (2079 women) or placebo (2074 women). 
The percentage of women with available data for the primary outcome was 97% 
(4038 of 4153 women). The incidence of live births after at least 34 weeks of gesta-
tion was 75% (1513 of 2025 women) in the progesterone group and 72% (1459 of 
2013 women) in the placebo group (relative rate, 1.03; 95% confidence interval 
[CI], 1.00 to 1.07; P = 0.08). The sensitivity analysis, in which missing primary 
outcome data were imputed, resulted in a similar finding (relative rate, 1.03; 95% 
CI, 1.00 to 1.07; P = 0.08). The incidence of adverse events did not differ signifi-
cantly between the groups.
CONCLUSIONS
Among women with bleeding in early pregnancy, progesterone therapy adminis-
tered during the first trimester did not result in a significantly higher incidence of 
live births than placebo. (Funded by the United Kingdom National Institute for 
Health Research Health Technology Assessment program; PRISM Current Con-
trolled Trials number, ISRCTN14163439.)
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Miscarriage affects one in five pregnancies.1 Miscarriage can cause ex-cessive bleeding, infection, and com-
plications associated with surgical treatment,2 
as well as substantial psychological harm, in-
cluding anxiety, depression, and post-traumatic 
stress disorder.3,4
Progesterone, which is produced by the corpus 
luteum in the ovary, is necessary to prepare the 
endometrium for implantation of the embryo 
and thus is an essential hormone for a success-
ful pregnancy. Additional progesterone is pro-
duced when an embryo implants in the endome-
trium and during early placental development. 
Subsequently, beginning at approximately 12 weeks 
of pregnancy, the placenta becomes the dominant 
source of progesterone.5
The physiological importance of progesterone 
has prompted researchers, physicians, and pa-
tients to consider progesterone supplementation 
during early pregnancy to prevent miscarriages. 
Progesterone supplementation in early pregnancy 
has been attempted in two contexts: the first is 
to prevent miscarriages in asymptomatic women 
who have a history of recurrent miscarriages, 
and the second is to rescue a pregnancy in 
women who have started to bleed during early 
pregnancy.6 We addressed the first scenario in a 
previous issue of the Journal7 and found no bene-
ficial effect of progesterone in women with a 
history of unexplained recurrent miscarriages. 
The current trial focuses on women with vaginal 
bleeding in early pregnancy.
A Cochrane review (originally published in 
2007 and last updated in 2018)6 of 7 randomized 
trials of progestational agents that involved 
women with bleeding in early pregnancy showed 
a significantly lower risk of miscarriages among 
women who received progesterone than among 
those who received placebo or no treatment 
(odds ratio, 0.64; 95% confidence interval [CI], 
0.47 to 0.87) but noted that the trials were small 
(the largest trial had a sample size of 191) and 
had methodologic weaknesses. Another Cochrane 
review of 13 trials of progestational agents that 
involved women with recurrent miscarriages was 
originally published in 2003 and was last up-
dated in 2018.8 The American College of Obste-
tricians and Gynecologists reviewed the evidence 
and concluded, “For threatened early pregnancy 
loss, the use of progestins is controversial, and 
conclusive evidence supporting their use is lack-
ing. Women who have experienced at least three 
prior pregnancy losses, however, may benefit from 
progesterone therapy in the first trimester.”9 We 
conducted the multicenter, randomized, parallel-
group, double-blind, placebo-controlled PRISM 
(Progesterone in Spontaneous Miscarriage) trial 
to investigate whether treatment with progester-
one would result in a higher incidence of live 
births among women with bleeding in early 
pregnancy than placebo.
Me thods
Trial Oversight
The PRISM trial was approved by the United 
Kingdom Medicines and Healthcare Products 
Regulatory Agency, the United Kingdom National 
Research Ethics Service Committee (South Cen-
tral Oxford), and the National Health Service 
research and development department at each 
participating hospital. The trial was conducted 
at clinics that are part of the trial research net-
work of the Tommy’s National Centre for Mis-
carriage Research, which is funded by Tommy’s 
Charity. Progesterone and placebo were pur-
chased from Besins Healthcare. This company 
had no role in the design of the trial; in the 
collection, analysis, or interpretation of the data; 
or in the preparation of the manuscript. Trial 
oversight and monitoring were provided by a 
trial steering committee and by an independent 
data and safety monitoring committee. The first, 
second, and last authors vouch for the accuracy 
and completeness of the data and analyses and 
for the fidelity of the trial to the protocol, avail-
able with the full text of this article at NEJM.org.
Trial Participants
The participants in the PRISM trial were re-
cruited at 48 hospitals in the United Kingdom. 
Women were eligible for enrollment in the trial 
if they were 16 to 39 years of age, if they had 
completed less than 12 weeks of pregnancy, if 
they presented with vaginal bleeding, and if they 
had an intrauterine gestational sac that was vis-
ible on ultrasonography. The upper threshold of 
39 years for maternal age was chosen because 
the probability of miscarriages due to chromo-
somal abnormalities increases with advancing 
age,10 and progesterone treatment could not be 
expected to prevent such miscarriages. Partici-
pants were excluded if at the time of presenta-
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tion the fetal crown–rump length was 7 mm or 
longer with no visible heartbeat; if the gesta-
tional sac was a mean of 25 mm or greater in 
diameter with no visible fetal pole on ultraso-
nography; if they had evidence of ectopic preg-
nancy; if they had life-threatening bleeding; if 
they had current or recent use of progesterone 
supplementation; if they had contraindications 
to progesterone therapy (i.e., a history of liver 
tumors; current genital or breast cancer, severe 
arterial disease, or acute porphyria; or a history 
during pregnancy of idiopathic jaundice, severe 
pruritus, or pemphigoid gestationis); or if they 
were participating in any other blinded, placebo-
controlled trials of medicinal products in preg-
nancy. All the participants provided written in-
formed consent.
Trial Assignments
Participants were randomly assigned, in a 1:1 
ratio, to administer to themselves vaginal supposi-
tories containing either 400 mg of micronized 
progesterone (Utrogestan, Besins Healthcare) 
or matching placebo twice daily, from the time 
of randomization through 16 completed weeks of 
gestation (or earlier if pregnancy ended before 
16 weeks). If vaginal administration was not 
preferred, participants could administer the sup-
positories rectally. Randomization was performed 
through a secure, centralized Internet facility 
with the use of minimization to balance the 
trial-group assignments according to maternal 
age (<35 years vs. ≥35 years), body-mass index 
(BMI [the weight in kilograms divided by the 
square of the height in meters], <30 vs. ≥30), 
fetal heart activity (present vs. absent), estimated 
gestation at presentation (<42 days vs. ≥42 days), 
and amount of vaginal bleeding (pictorial blood-
loss assessment chart [PBAC] score of ≤2 vs. 
score of ≥3; scores range from 1 to 4, with 
higher scores indicating greater vaginal blood 
loss).11 The appearance, route, and timing of ad-
ministration of progesterone and placebo were 
identical. Participants, physicians, and trial nurses 
were unaware of the trial-group assignments 
throughout the course of the trial.
Outcome Measures
The primary outcome was the birth of a live-
born baby after at least 34 completed weeks of 
gestation. Secondary outcomes included the time 
from conception to the end date of pregnancy, 
ongoing pregnancy at 12 weeks of gestation, 
miscarriage (defined as loss of pregnancy before 
24 weeks of gestation), live birth before 34 weeks 
of gestation, ectopic pregnancy, stillbirth (defined 
as intrauterine death after at least 24 weeks of 
gestation), termination of pregnancy, the week of 
gestation at delivery, birth weight, size (small or 
large) for gestational age, preeclampsia, Apgar 
scores, survival at 28 days of neonatal life, and 
congenital abnormalities, as well as other ante-
natal, intrapartum, postpartum, and neonatal 
outcomes. A detailed list of all secondary out-
comes is provided in the Supplementary Appen-
dix, available at NEJM.org. We attempted to 
collect outcome data for all participants who 
underwent randomization, regardless of adher-
ence to the trial-group assignment.
Statistical Analysis
We calculated that 1972 women would need to 
be included in each trial group to provide 90% 
power to detect a minimally important absolute 
difference of 5 percentage points between the 
progesterone group and the placebo group in the 
incidence of live births after at least 34 weeks of 
gestation (65% vs. 60%), at a two-sided alpha 
level of 0.05. This minimally important differ-
ence was chosen on the basis of a national survey 
of clinical practitioners in the United Kingdom. 
We planned to include 4150 women in the trial 
to account for an expected 5% loss to follow-up.
The analysis of the primary outcome was 
performed according to the intention-to-treat 
principle; a main analysis of all available data 
was supplemented by a sensitivity analysis of the 
primary outcome that included all participants 
and took into account any missing data with the 
use of multiple imputation.12 A Poisson regres-
sion model with robust standard errors was used 
to estimate the relative rates and corresponding 
95% two-sided confidence intervals, with adjust-
ment for the minimization variables. This meth-
od has been shown to be appropriate and to be 
less prone to convergence issues than other 
similar methods.13
For the primary outcome, a P value was gener-
ated with the use of a two-sided chi-square test. 
The statistical analysis plan did not include a 
provision for correction for multiplicity when 
the analyses of the secondary outcomes were 
performed. Therefore, the results are reported as 
point estimates and 95% confidence intervals, 
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without P values. For continuous outcomes, a 
linear regression model was used to estimate 
mean differences, with the same adjustment that 
was used in the analysis of the primary out-
come. The widths of the confidence intervals 
were not adjusted for multiplicity, so the inter-
vals should not be used to infer definitive treat-
ment effects.
We analyzed the treatment effect on the pri-
mary outcome in prespecified subgroups defined 
according to maternal age (<35 years vs. ≥35 
years), BMI (<30 vs. ≥30), fetal heart activity 
(present vs. absent), estimated gestation at pre-
sentation (<6 weeks vs. 6 to <9 weeks vs. ≥9 
weeks), amount of vaginal bleeding (PBAC score 
of ≤2 vs. score of ≥3),11 number of previous mis-
carriages (0 vs. 1 or 2 vs. ≥3), number of gesta-
tional sacs (1 vs. ≥2), race (white, black, south 
Asian, or other), history of polycystic ovaries (yes 
vs. no), and previous cervical excision (yes vs. no). 
The effects of these subgroups were examined 
by adding the variables for the interaction of 
subgroup with trial group to the regression 
model; a chi-square test was used to determine 
whether the effects of progesterone and placebo 
differed in the various subgroups.
Interim analyses of principal safety and ef-
fectiveness outcomes were performed on behalf 
of the data and safety monitoring committee by 
the trial statistician (who remained unaware 
of the treatment assignments) on two occasions. 
Because these analyses were performed with the 
use of the Peto principle,14 no adjustment was 
made in the final P values to determine signifi-
cance.
R esult s
Trial Participants
From May 19, 2015, through July 27, 2017, a total 
of 12,862 women were identified as being eligi-
ble for the PRISM trial; of these women, 4153 
were randomly assigned to receive either proges-
terone (2079 women) or placebo (2074 women) 
(Fig. 1). The percentage of women with available 
data for the primary outcome was 97% (4038 of 
4153 women). Demographic and baseline char-
acteristics were similar in the two trial groups 
(Table 1, and Table S1 in the Supplementary Ap-
pendix). Information on the route of administra-
tion was available for 88% (3662 of 4153) of the 
women: 99% (3611 of 3662 women) administered 
the suppositories vaginally and 1% (51 of 3662 
women) administered them rectally.
Outcomes
The incidence of live births after at least 34 weeks 
of gestation was 75% (1513 of 2025 women) in 
the progesterone group and 72% (1459 of 2013 
women) in the placebo group (relative rate, 1.03; 
95% CI, 1.00 to 1.07; P = 0.08). The sensitivity 
analysis, in which multiple imputation was used 
for missing data, did not change the findings 
(relative rate, 1.03; 95% CI, 1.00 to 1.07; P = 0.08).
The incidence of ongoing pregnancy at 12 
weeks was 83% (1672 of 2025 women) in the 
progesterone group and 80% (1602 of 2013 
women) in the placebo group (relative rate, 1.04; 
95% CI, 1.01 to 1.07). The incidence of miscar-
riage was 20% (410 of 2025 women) in the pro-
gesterone group and 22% (451 of 2013 women) 
in the placebo group (relative rate, 0.91; 95% CI, 
0.81 to 1.01). The results of all the other second-
ary outcomes are presented in Table 2, and in 
Table S2 in the Supplementary Appendix.
A significant subgroup effect was identified 
for only 1 of the 10 prespecified subgroups — 
the subgroup of participants defined according 
to the number of previous miscarriages. The inci-
dence of live births in the subgroup of women 
who had no previous miscarriages was 74% in 
the progesterone group and 75% in the placebo 
group (relative rate, 0.99; 95% CI, 0.95 to 1.04); 
the incidence among women who had one or 
two previous miscarriages was 76% and 72%, 
respectively (relative rate 1.05; 95% CI, 1.00 to 
1.12); and the incidence among women who had 
three or more previous miscarriages was 72% 
and 57%, respectively (relative rate, 1.28; 95% 
CI, 1.08 to 1.51) (P = 0.007 for the interaction 
between trial group and the number of miscar-
riages) (Fig. 2). The results of two post hoc sub-
group analyses in which we categorized the 
number of previous miscarriages differently from 
the subgroup analysis described here are provided 
in Figure S1 in the Supplementary Appendix.
There was no significant between-group dif-
ference in the percentage of participants who 
had either a maternal or neonatal serious ad-
verse event (5% [105 of 2025 participants] in the 
progesterone group and 5% [98 of 2013 partici-
pants] in the placebo group), including specifi-
cally the percentage of babies who had neonatal 
congenital abnormalities (3.4% in each group), 
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nor was there any significant between-group dif-
ference in the number of maternal or neonatal 
serious adverse events. A summary of serious 
adverse events is provided in Table S3 in the 
Supplementary Appendix.
Discussion
Our large multicenter, randomized, double-blind, 
placebo-controlled trial showed that among 
women with bleeding in early pregnancy, pro-
gesterone therapy administered during the first 
trimester of pregnancy did not result in a signifi-
cantly higher incidence of live births after at 
least 34 weeks of gestation than placebo. There 
was also no significant difference between the 
groups in the incidence of miscarriage or still-
birth. Although there appeared to be slightly 
more ongoing pregnancies at 12 weeks in the 
progesterone group than in the placebo group, 
an inference of benefit cannot be drawn because 
the confidence interval for the relative rate was 
not adjusted for multiplicity of testing.
The large sample size in our trial allowed in-
vestigation of the primary outcome in prespeci-
fied subgroups. Among the 10 subgroup analyses, 
Figure 1. Enrollment, Randomization, and Follow-up.
12,862 Were eligible
4153 Underwent randomization
23,775 Patients were assessed for eligibility
10,913 Were not eligible
3373 Had vaginal bleeding stop >4 days
before screening
2756 Had last menstrual period >12 weeks
before screening
1444 Had evidence of ectopic pregnancy
1323 Were >39 yr of age
811 Had current or recent use of progesterone
supplement
530 Were <16 yr of age
476 Were unable to understand English
115 Were participating in another clinical trial
65 Had contraindication to progesterone
therapy
20 Had life-threatening bleeding
8709 Declined to participate
2079 Were assigned to receive
progesterone
2074 Were assigned to receive
placebo
10 Withdrew
44 Were lost to follow-up
20 Withdrew
41 Were lost to follow-up
2025 Had data available for analysis of 
primary outcome
54 Had missing responses imputed
and were included in sensitivity analysis
2013 Had data available for analysis of 
primary outcome
61 Had missing responses imputed
and were included in sensitivity analysis
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1 showed differential effects of progesterone: the 
effect of progesterone in women with bleeding 
in early pregnancy differed according to the 
number of previous miscarriages, with a sugges-
tion of benefit among women who had had 
three or more previous miscarriages. Previous 
reports have indicated a steep and proportionate 
increase in the loss of chromosomally normal 
pregnancies (i.e., euploid miscarriages) with in-
creasing number of previous miscarriages.15 
Given that the potential benefit of progesterone 
therapy would be expected to be specific to eu-
ploid pregnancies, an increasing level of benefit 
in women with increasing number of previous 
Characteristic
Progesterone 
(N = 2079)
Placebo 
(N = 2074)
Demographic characteristics
Maternal age†
Mean — yr 30.6±5.1 30.5±5.1
Distribution — no. (%)
<35 yr 1604 (77) 1601 (77)
≥35 yr  475 (23)  473 (23)
Body‑mass index†
Mean 26.4±6.2 26.5±6.3
Distribution — no. (%)
<30 1589 (76) 1589 (77)
≥30 490 (24)  485 (23)
Race — no. (%)‡
White 1714 (82) 1742 (84)
Black  84 (4)  79 (4)
South Asian 114 (5) 102 (5)
Other 167 (8) 151 (7)
Pregnancy history
Nulliparous — no. (%)  474 (23) 514 (25)
Previous preterm births at ≥24 wk to <34 wk — no. (%)  83 (4) 90 (4)
Previous miscarriages at <24 wk of gestation — no. (%)
0 1145 (55) 1157 (56)
1 or 2  792 (38) 758 (37)
≥3 142 (7) 159 (8)
No. of previous miscarriages — median (IQR) 0 (0–1) 0 (0–1)
Amount of bleeding as assessed by PBAC score†§ — no. (%)
≤2 1913 (92) 1907 (92)
≥3 166 (8) 167 (8)
Fetal heart activity at presentation — no. (%)†¶ 1710 (82) 1701 (82)
*  Plus–minus values are means ±SD. There were no significant differences between the two groups in the characteristics 
listed. Further details regarding baseline characteristics are provided in Table S1 in the Supplementary Appendix. Per‑
centages may not sum to 100 because of rounding. IQR denotes interquartile range.
†  This variable was a minimization variable.
‡  Race was reported by the participant.
§  Pictorial blood‑loss assessment chart (PBAC) scores range from 1 to 4, with higher scores indicating greater vaginal 
blood loss.11
¶  If more than one fetus was present, this variable was characterized as any fetus that had heart activity at presentation.
Table 1. Demographic and Baseline Characteristics of the Participants.*
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miscarriages is consistent with our understand-
ing of the biologic factors associated with risk of 
miscarriage. A history of miscarriage is one of 
only two stratification or prognostic risk factors 
(the other being maternal age) cited in the 2017 
guideline of the European Society of Human 
Reproduction and Embryology on recurrent preg-
nancy loss as being useful for identifying high-
risk patients.16 However, we did not identify this 
subgroup as one of special interest a priori in 
our statistical analysis plan,17 and multiple com-
parisons were performed (without adjustment 
for multiplicity); thus, this observation requires 
validation.
Some limitations of our trial should be con-
sidered. First, we studied a vaginal preparation 
of progesterone, at a dose of 400 mg twice daily, 
and it is possible that the results observed with 
this regimen are not generalizable to women 
receiving other doses and preparations by other 
Outcome
Progesterone 
(N = 2025)
Placebo 
(N = 2013)
Relative Rate or 
Mean Difference 
(95% CI)†
Primary outcome — no. (%)
Live birth at ≥34 wk 1513 (75) 1459 (72) 1.03 (1.00 to 1.07)‡
Secondary maternal outcomes — no. (%)§
Ongoing pregnancy at 12 wk 1672 (83) 1602 (80) 1.04 (1.01 to 1.07)
Miscarriage, defined as loss of pregnancy at <24 wk¶  410 (20) 451 (22) 0.91 (0.81 to 1.01)
Live birth at <34 wk  68 (3) 64 (3) 1.06 (0.76 to 1.49)
Ectopic pregnancy 0 2 (<1) —
Stillbirth, defined as intrauterine death at ≥24 wk     5 (<1) 6 (<1) 0.82 (0.25 to 2.66)
Termination of pregnancy‖  34 (2) 36 (2) 0.94 (0.59 to 1.50)
Secondary neonatal outcomes among women with live 
births at ≥24 wk§
Gestational age at delivery**
Wk of gestation 38 wk 4 days±2 wk  
4 days
38 wk 4 days±2 wk  
3 days
0.11 days (−0 wk 1 day 
 to 0 wk 2 days)†
No. of women 1581 1521
Birth weight††
Mean weight — g 3242±656 3261±659 −21 (−67 to 25)†
No. of infants 1604 1539
Death at 28 days of neonatal life — no./total no. (%)‡‡ 8/1605 (<1) 2/1533 (<1) 3.84 (0.80 to 18.40)†
*  Plus–minus values are means ±SD. Additional data on outcomes are provided in Table S2 in the Supplementary Appendix.
†  Relative rates are shown for the primary outcome, all secondary maternal outcomes, and the secondary neonatal outcome of death at 28 
days of neonatal life. The mean difference is shown for the secondary neonatal outcomes of gestational age at delivery and birth weight. 
For binary outcomes, a relative rate of less than 1 favors the progesterone group, except for live birth after at least 34 weeks of gestation 
and ongoing pregnancy at 12 weeks, for which a relative rate greater than 1 would favor progesterone. For continuous outcomes, a mean 
difference of less than 0 favors the progesterone group. The widths of the confidence intervals were not adjusted for multiplicity, so the 
 intervals should not be used to infer definitive treatment effects.
‡  P = 0.08.
§  Five women in the progesterone group and three women in the placebo group had both a live birth after at least 34 weeks of gestation and 
a miscarriage; one woman in the placebo group had both a termination of pregnancy and a miscarriage; and one woman in the placebo 
group had both a live birth before 34 weeks and a stillbirth.
¶  The median gestational age was 8 weeks (interquartile range, 7 to 10) in both trial groups.
‖  The reasons for termination of pregnancy in the progesterone group were social for 13 women and medical for 21 women. The reasons 
for termination of pregnancy in the placebo group were social for 12 women and medical for 24 women. The median gestational age was 
14 weeks (interquartile range, 12 to 19) in the progesterone group and 15 weeks (interquartile range, 11 to 18) in the placebo group.
**  The gestational age at delivery was unknown for the infants of two women in the placebo group.
††  The birth weight was unknown for the infants of 6 women in the progesterone group and 6 women in the placebo group.
‡‡  The neonatal vital status at 28 days of life was unknown for 17 women (5 in the progesterone group and 12 in the placebo group).
Table 2. Primary Outcome and Secondary Outcomes.*
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routes. Micronized vaginal progesterone has an 
identical molecular structure to natural proges-
terone, whereas other formulations of progesta-
tional agents have a different molecular structure 
and therefore potentially different mechanisms 
of action and pharmacologic features. Immuno-
modulatory effects of progesterone at the tropho-
blastic–decidual interface have been proposed as 
a mechanism whereby progesterone might pre-
vent miscarriage.18 The vaginal route delivers a 
greater proportion of drug to the relevant site 
(i.e., the uterus) with the use of the “first uterine 
pass” effect.19,20 Furthermore, trials that have 
evaluated vaginal progesterone in the prevention 
Figure 2. Subgroup Analysis.
Shown is the analysis of live births after at least 34 weeks of gestation (the primary outcome) in prespecified subgroups. The widths of 
the confidence intervals were not adjusted for multiplicity, so the intervals should not be used to infer definitive treatment effects. The 
size of each black square is proportional to the total number of women in the subgroup. The body‑mass index is the weight in kilograms 
divided by the square of the height in meters. The score on the pictorial blood‑loss assessment chart (PBAC) indicates the amount of 
vaginal bleeding; scores range from 1 to 4, with higher scores indicating greater vaginal blood loss.11 Race was reported by the participant. 
LLETZ denotes large loop excision of the transformation zone of the cervix (also known as the loop electrosurgical excision procedure [LEEP]).
1.00 1.25
Progesterone BetterPlacebo Better
Placebo Risk Ratio (95% CI)ProgesteroneSubgroup
0.75
P Value for
Interaction
no. of events/total no.
1.12 (0.95–1.33)
1.03 (0.99–1.06)
0.98 (0.88–1.10)
1.04 (1.00–1.08)
1.04 (0.91–1.19)
0.97 (0.82–1.15)
1.04 (1.00–1.07)
0.90 (0.69–1.19)
1.08 (0.87–1.35)
1.03 (1.00–1.07)
1.03 (1.00–1.07)
1.28 (1.08–1.51)
1.05 (1.00–1.12)
0.99 (0.95–1.04)
1.00 (0.88–1.14)
1.03 (1.00–1.07)
1.04 (0.91–1.18)
1.05 (1.01–1.10)
0.98 (0.94–1.03)
1.02 (0.99–1.06)
1.10 (0.94–1.30)
1.07 (0.99–1.15)
1.02 (0.98–1.06)
1.03 (0.99–1.07)
1.05 (0.97–1.13)
0.70
0.31
0.37
0.13
0.61
0.007
0.34
0.87
0.35
0.30
Maternal age
<35 yr
≥35 yr
Body-mass index
<30
≥30
Fetal heart activity
Present
Absent
Estimated gestation at presentation
<6 wk
6 wk to <9 wk
≥9 wk
Amount of bleeding on PBAC
≤2
≥3
No. of previous miscarriages
0
1–2
≥3
No. of gestational sacs
1
≥2
Race
White
Black
South Asian
Other
History of polycystic ovaries
Yes
No
Previous LLETZ
Yes
No
All Participants
1148/1555
311/458
1128/1541
331/472
1304/1648
155/365
202/365
832/1162
425/486
1344/1853
115/160
840/1127
534/738
  85/148
1432/1975
27/38
1245/1697
46/75
  69/101
  99/140
161/221
1297/1791
  68/102
1391/1911
1459/2013
1184/1558
329/467
1155/1548
358/477
1347/1672
166/353
209/358
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of preterm birth have shown its effectiveness 
when administered by this route.21,22
Second, we started progesterone treatment 
only in women who had an intrauterine sac; 
therefore, our trial cannot provide evidence on 
the effects of earlier use of progesterone, before a 
pregnancy sac is visible on an ultrasound exami-
nation. Third, the participants discontinued pro-
gesterone at 16 weeks of gestation; however, we 
consider it to be unlikely that therapy beyond 
this time would have affected the outcomes re-
lated to miscarriage. Finally, although we found 
no increase in the risk of congenital abnormali-
ties among babies of women treated with pro-
gesterone, the trial was not powered for such 
rare outcomes.
In conclusion, treatment with progesterone did 
not result in significant improvement in the in-
cidence of live births among women with vagi-
nal bleeding during the first 12 weeks of preg-
nancy.
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